Sglt Inhibitors Explored As Type 1 Diabetes Treatment | Latest News RSS feed

Sglt Inhibitors Explored As Type 1 Diabetes Treatment - Latest News


Liraglutide: A New Player in Type 1 Diabetes Treatment?

In 2011, soon after liraglutide was approved in the United States for the treatment ... being studied in type 1 diabetes go, she believes liraglutide and metformin are generally safer than the sodium- ... read more

Benefits of SGLT2 Inhibitors in Patients With or Without History of CVD

Individuals with either type 1 diabetes or gestational diabetes were not enrolled in the study. Patients were matched (1:1) and placed into one treatment group, which were as follows: 1) SGLT2 inhibit... read more

New Data Show Lilly's Trulicity® (dulaglutide) in Combination with an SGLT-2 Inhibitor Improves Blood Sugar Control in People with Type 2 Diabetes

1 These data were published online ... that the combination of once-weekly Trulicity and an SGLT-2 inhibitor shows significant promise in helping more people with type 2 diabetes reach their treatment ... read more

Looking for another news?


FDA Advisory Committee Recommends the Investigational SGLT2 Inhibitor Dapagliflozin for the Treatment of Type 2 Diabetes in Adults

Dapagliflozin, an investigational compound in the U.S., was the first SGLT2 inhibitor to be approved anywhere in the world. Dapagliflozin is currently approved under the trade name [Forxiga]™ for the ... read more


New class of type 2 diabetes drug associated with rare, life-threatening outcome

A new class of drugs, known as SGLT2 inhibitors, is increasingly being prescribed for the treatment of type 2 ... is usually associated with type 1 diabetes - it's very uncommon for people with type 2 ... read more

Sanofi: EMA to review sotagliflozin as potential treatment for type 1 diabetes

If approved, the oral treatment would be ... sugar control in adults with type 1 diabetes mellitus. Developed in partnership with Lexicon Pharmaceuticals, Inc., sotagliflozin is an investigational dua... read more

FDA to review Zynquista™ (sotagliflozin) as potential treatment for type 1 diabetes

“After decades of little change and innovation, the treatment of type 1 diabetes has begun to shift significantly and, if approved, our dual SGLT-1 and SGLT-2 inhibitor, Zynquista, would be the first ... read more

Upcoming Conversation With An Expert: Understanding The Potential Of Lexicon's Sotagliflozin As A Novel Treatment For Diabetes

Type ... to SGLT-1 in the presence of an SGLT-2 inhibitor. (Abdul-Ghani et al. Diabetes. 2013) Combined with its ability to combat hypertension and obesity, sotagliflozin’s efficacy in treating diabet... read more

New class of type 2 diabetes drug associated with rare, life-threatening outcome

A new class of drugs, known as SGLT2 inhibitors, is increasingly being prescribed for the treatment ... diabetes taking SGLT2 inhibitors prompted the FDA to issue a warning in 2015 about the class of ... read more

Canagliflozin Renal Outcomes Study Is Halted Early for Efficacy

An early halt has been called for a phase 3 randomized clinical trial investigating renal outcomes for the sodium-glucose cotransporter-2 (SGLT2) inhibitor ... type 2 diabetes, an estimated glomerular ... read more

AstraZeneca submits sNDA in Japan for Forxiga in type-1 diabetes

in Japan for the use of Forxiga (dapagliflozin), a selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, as an oral adjunct treatment to insulin in adults with type-1 diabetes (T1D). The submis... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us